Ixekizumab in hidradenitis suppurativa in a psoriatic patient

G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.

Authors

Giulia Odorici¹, Giovanni Pellacani², Andrea Conti²

Affiliations

¹ Unit of Dermatology, Department of Surgical, Medical, Dental and Morphological Sciences with Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy - giulai87@hotmail.com.
² Unit of Dermatology, Department of Surgical, Medical, Dental and Morphological Sciences with Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.

PMID: 30636397
DOI: 10.23736/S0392-0488.18.06135-7

No abstract available

Publication types

Case Reports

MeSH terms

Adalimumab / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / complications
Drug Substitution
Hidradenitis Suppurativa / complications
Hidradenitis Suppurativa / drug therapy*
Humans
Immunocompromised Host
Interleukin-17 / antagonists & inhibitors*
Latent Tuberculosis / complications
Male
Middle Aged
Psoriasis / complications*
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Interleukin-17
Tumor Necrosis Factor-alpha
ixekizumab
secukinumab
Adalimumab